In August 2022, the Inflation Reduction Act, or IRA, was signed into law. The IRA includes multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. For example, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the product’s price increases faster than the rate of inflation.
All entries for: Dermatology
March 19, 2026
Pelthos Therapeutics
Negative Outlook
Durham, NC
51-200 employees
In addition, the Inflation Reduction Act of 2022 (“IRA”) which among other things, extended enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminated the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have an adverse effect on customers for ZELSUVMI and our product candidates, if approved, and, accordingly, our financial operations.
Disease Area: Dermatology, Infectious Diseases
Drug Type: Small Molecule
March 18, 2026
Vyome Holdings
Neutral Outlook
Cambridge, MA
1-50 employees
Further, judicial challenges to the IRA may have an impact on the implementation of the IRA’s provisions; and the overall effects of the IRA on Bio’s business and the healthcare industry in general is not yet known.
Disease Area: Dermatology, Immune Diseases
Drug Type: Small Molecule
March 13, 2026
Nektar Therapeutics
Neutral Outlook
San Francisco, CA
51-200 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Dermatology, Endocrinology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic
March 12, 2026
Acurx Pharmaceuticals, Inc./NY
Neutral Outlook
Staten Island, NY
1-50 employees
However, the IRA’s impact on the pharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints.
Disease Area: Dermatology, Infectious Diseases
Drug Type: Small Molecule
March 11, 2026
Verrica Pharmaceuticals Inc.
Neutral Outlook
West Chester, PA
51-200 employees
It is unclear how such challenges and the healthcare reform measures of the current administration will impact the ACA and our business.
Disease Area: Dermatology, Infectious Diseases, Oncology
Drug Type: Biologic, Small Molecule
March 10, 2026
Q32 Bio Inc.
Neutral Outlook
Waltham, MA
1-50 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Dermatology, Immune Diseases
Drug Type: Biologic